Novo Nordisk stock heads before the bell after mixed trial news

At the close on September 7, 2026, Novo Nordisk stock finished at DKK 298.62 on Nasdaq Copenhagen, down 0.09 percent. Reuters said the company halted two ziltivekimab trials, while STEP Young data showed 40.4 percent of children were no longer classified as having obesity.

Novo Nordisk stock closed at DKK 298.62 on Nasdaq Copenhagen on September 7, 2026, down 0.09 percent. The move followed mixed clinical headlines that left the shares near the prior close of DKK 298.90.

September 7, 2026 close

Novo Nordisk A/S (ISIN DK0062498333) fell after Reuters reported that the company halted two additional phase III ziltivekimab trials. The same session also brought STEP Young results showing that 40.4 percent of children aged 6 to under 12 were no longer classified as having obesity after 68 weeks.

The stock's close sat within the day's range of DKK 297.70 to DKK 301.10 and came against a market backdrop in which the Nasdaq Copenhagen session ended lower. Market data also showed the shares only fractionally below the prior close, with the session's change at minus 0.09 percent.

Today before the open

Today the main company item is the follow-through from the STEP Young release and the halted ziltivekimab studies. The company said the detailed STEP Young results will be presented at ObesityWeek 2026 in Washington, DC, from November 14 to November 17.